Bayer HealthCare and Teva Pharmaceutical Industries TEVA announced today that they have signed an agreement in which Bayer
will acquire the U.S. based animal health business of Teva for up to 145
million USD. The purchase price includes an upfront payment of 60
million USD plus a total of 85 million USD in milestone payments, which
are linked to the successful and timely achievement of manufacturing and
sales targets. The acquisition allows Bayer to expand its companion and
food animal product lines in the United States by integrating the
acquired assets into its animal health business. The transaction
reflects Teva's commitment to focus its efforts on human health and its
core expertise of providing generic and branded medicines to patients
around the world.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in